Gonorrhea - Pipeline Review, H2 2020
発行: Global Markets Direct
ページ情報: 英文 130 Pages
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H2 2020, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.
Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 4, 11, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 3 molecules, respectively.
Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.